Abstract
The incidence and prevalence of hepatocellular carcinoma (HCC) is growing worldwide, leading to high mortality rates. The disease occurs mainly in cirrhotic patients, and the cure can be reached only when it is diagnosed early or when the tumor is submitted to adjuvant therapies to reduce the tumor size, being the transarterial chemoembolization (TACE) the most used approach to achieve th…